Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lexicon Pharmaceuticals
Biotech
Novo inks $1B deal for Lexicon’s preclinical obesity prospect
Novo is betting $75 million in upfront and near-term milestone payments for rights to a preclinical asset that paired well with semaglutide in mice.
Nick Paul Taylor
Mar 28, 2025 7:30am
Lexicon feels the pain as non-opioid data underwhelm investors
Mar 3, 2025 9:52am
Vincerx acquisition leads to C-suite shake-up—Chutes & Ladders
Jan 3, 2025 8:30am
BridgeBio, Ipsen, George Medicines and more—Chutes & Ladders
May 3, 2024 8:30am
Longtime BioMarin CEO hands off baton—Chutes & Ladders
Nov 3, 2023 9:30am
CEPI's founding CEO to lead Wellcome—Chutes & Ladders
Oct 13, 2023 9:30am
